Search results
FDA approves Kevzara for children with pJIA over 63kg By Investing.com
Investing.com· 6 days agoRegeneron (NASDAQ:REGN) Pharmaceuticals, Inc. (NASDAQ:REGN) and its partner Sanofi (NASDAQ:SNY) have...
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $1,229.00
ETF DAILY NEWS· 4 days agoRegeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its target price upped by Royal Bank of Canada from $1,200.00 to $1,229.00 in a research report sent to investors ...
...Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market - Regeneron...
Benzinga· 4 days agoAnalyst projects Regeneron's Dupixent to drive COPD sales surge, envisioning $20B market by 2026 on larger addressable market.
Top Stock Reports for Procter & Gamble, ServiceNow & Lockheed Martin
Zacks via Yahoo Finance· 6 days agoToday's Research Daily features new research reports on 16 major stocks, including The Procter &...
Why Regeneron Stock Finally Joined The 1,000-Club
Investor's Business Daily· 5 days agoEnthusiasm is growing for a looming approval in COPD treatment.
Regeneron holds Buy rating and price target from TD Cowen By Investing.com
Investing.com· 3 days agoOn Friday, TD (TSX:TD) Cowen maintained a Buy rating on shares of Regeneron (NASDAQ:REGN)...
Intellia (NTLA) Banks on Genome Editing Pipeline Amid Rivalry
Zacks via Yahoo Finance· 3 days agoIntellia's (NTLA) lead genome-editing candidate, NTLA-2001 being developed to treat transthyretin...
Intellia (NTLA) Banks on Genome Editing Pipeline Amid Rivalry
Zacks· 3 days agoIntellia's (NTLA) lead genome-editing candidate, NTLA-2001 being developed to treat transthyretin (ATTR) amyloidosis, holds promise. Other pipeline candidates are also progressing well.
Market Today: Boeing Delays 737 Production, Pfizer Extends Losse
Guru Focus· 2 days agoMarket Performance Overview The S&P 500 and Nasdaq Composite hit fresh record highs this week,...
CapitaLand Investment Further Increases Focus on Reducing Scope 3 Carbon Emissions as Part of its...
Morningstar· 2 days agoCLI continues to intensify efforts to reduce Scope 1 and 2 emissions through on-ground actions and innovation SINGAPORE, June 15, 2024 /PRNewswire/ -- CapitaLand Investment Limited (CLI) has incorporated three new Scope 3 categories deemed material